Valuation: Catalyst Pharmaceuticals, Inc.

Market Cap 3.85B 3.34B 3.16B 2.86B 5.37B 370B 5.41B 37.68B 14.5B 188B 14.48B 14.16B 598B P/E 2024
15.9x
P/E 2025 13.9x
Enterprise Value 3.15B 2.73B 2.58B 2.33B 4.38B 302B 4.41B 30.78B 11.84B 153B 11.83B 11.56B 488B EV / Sales 2024
4.02x
EV / Sales 2025 3.67x
Free-Float
99.94%
Yield 2024 *
-
Yield 2025 -
1 day+0.03%
3 months+0.38%
6 months+35.56%
Current year+34.92%
Current year 22.13
Extreme 22.13
32.56
1 year 19.05
Extreme 19.05
32.56
3 years 11.55
Extreme 11.55
32.56
5 years 4.81
Extreme 4.81
32.56
10 years 0.94
Extreme 0.9414
32.56
Manager TitleAgeSince
Chief Executive Officer 65 2023-12-31
Director of Finance/CFO 55 2023-12-31
Chief Tech/Sci/R&D Officer 62 2025-05-31
Director TitleAgeSince
Director/Board Member 48 2026-07-14
Director/Board Member - 2026-07-14
Director/Board Member - 2026-07-14
Date Insider Type Main position Quantity % Market Cap. Importance
7/15/26 Issuer sale

Director

-63,583 0.0519%
7/15/26 Issuer sale

Director

-130,857 0.1069%
7/15/26 Issuer sale

Executive/Senior Manager

-1,051,183 0.8587%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%-.--%+59.36%+152.73% 3.85B
-2.47%-4.47%+35.19%-5.99% 79.26B
-0.87%+0.93%-14.42%-34.96% 58.62B
-1.99%+2.45%+502.05%+25.46% 58.56B
-0.56%-1.94%-11.70%+25.63% 48.75B
-0.29%+1.45%+2.14%+149.29% 46.32B
-0.55%+1.73%+50.83%-15.16% 32.12B
-0.37%-2.14%+46.43%+94.63% 24.77B
-0.58%-3.87%-1.92%+136.89% 21.5B
-1.92%-3.81%+61.03%+96.07% 15.97B
Average -0.64%-0.94%+72.90%+62.46% 38.97B
Weighted average by Cap. -0.73%-1.10%+89.35%+36.06%

Financials

2024 2025
Net sales 492M 426M 403M 365M 684M 47.17B 690M 4.81B 1.85B 23.92B 1.85B 1.81B 76.28B 589M 510M 482M 437M 820M 56.5B 826M 5.76B 2.21B 28.65B 2.21B 2.16B 91.36B
Net income 164M 142M 134M 122M 228M 15.72B 230M 1.6B 616M 7.97B 616M 602M 25.42B 214M 186M 176M 159M 298M 20.56B 301M 2.09B 806M 10.42B 805M 787M 33.25B
Net Debt -514M -446M -421M -381M -716M -49.34B -721M -5.03B -1.93B -25.02B -1.93B -1.89B -79.79B -706M -612M -579M -524M -983M -67.76B -990M -6.9B -2.66B -34.36B -2.65B -2.59B -110B
Logo Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Employees
182
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. CPRX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!